AGRX Shariah Compliance
Screening Methodology: AAOIFI
NOT HALAL
Last Updated: July 27, 2024
Report Source: 2024 1st Quarter Report
Agile Therapeutics Inc. Stock Analysis AGRX
Agile Therapeutics, Inc. is a healthcare company, which engages in the development and commercialization of transdermal patches. The company is headquartered in Princeton, New Jersey and currently employs 19 full-time employees. Its product and product candidates are designed to provide women with contraceptive options that offer freedom from taking a daily pill, without committing to a longer-acting method. Its initial product, Twirla, (levonorgestrel and ethinyl estradiol), a transdermal system, is a non-daily prescription contraceptive. Twirla is based on its proprietary transdermal patch technology, called Skinfusion, which is designed to allow drug delivery through the skin. Twirla (levonorgestrel and ethinyl estradiol) transdermal system is a once-weekly combined hormonal contraceptive (CHC) patch that contains the active ingredients levonorgestrel (LNG), a type of progestin, and ethinyl estradiol (EE), a type of estrogen. Its potential product pipeline consists of two types of product candidates: a progestin-only (P-only) contraceptive patch and potential Twirla line extensions.
Read More Agile Therapeutics Inc (AGRX) Chart
Key Statistics of Agile Therapeutics Inc (AGRX)
Key statistics in the stock market are essential financial indicators that measure a company's performance, valuation, profitability, and risk.
Today's Range
Today's Open
$1.51Volume
120.94KP/E Ratio (TTM)
-52 Week Range
Market Cap
10.43MAvg. Volume
67.04KDividend Yield
-Financial Metrics & Statements of Agile Therapeutics Inc (AGRX)
FAQ's for Agile Therapeutics Inc (AGRX)
- According to Musaffa’s Shariah screening methodology, Agile Therapeutics Inc (AGRX) is currently classified as NOT HALAL as of July 2024. The classification is based on an evaluation of the company’s business activities and financial ratios to determine whether it meets Islamic investment guidelines.